Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2011. The report details a specific corporate action regarding share repurchases executed on July 22, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on share capital movements.
- Shares Purchased: 1,000,000 Ordinary shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,344.5 pence per share; lowest price paid was 1,334.0 pence per share.
- Treasury Holdings (Settled): 487,884,284 shares (8.71% of total issued share capital).
- Treasury Holdings (Including Unsettled): 491,504,284 shares (9.61% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,115,694,674 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,000,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.61% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves strictly as a notification of the share buyback transaction and the resulting capital structure.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (487,884,284 settled) against the company's latest capitalization table.
- Confirm the total issued share capital excluding Treasury shares (5,115,694,674) for voting rights calculations under Disclosure and Transparency Rules.
- Review the price range paid (1,334.0 to 1,344.5 pence) to assess the cost of capital relative to market prices on July 22, 2011.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.